65,437 trials
Renal Cell Carcinoma
Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants
Musculoskeletal Pain
Primary: Change in Pain From Before Medication Administered (Baseline) to One-hour Post-baseline — 3.0; 3.0; 3.4; 3.1 Units on a scale — p=0.69
Neuroendocrine Tumors
Primary: Overall Response Rate (ORR) — 1; 8; 8; 3 Participants
Glioblastoma · Astrocytoma, Grade IV · Giant Cell Glioblastoma
Primary: Median Overall Survival — 16; 20; 19 months — p=0.072
Dental Caries on Pit and Fissure Surface
Primary: Sealant Retention Percentage at 12 Months After Treatment — 59; 66 teeth
Bilateral Nasal Polyposis
Primary: Change From Baseline to Week 12 in Nasal Polyp Score as Measured by Nasal Endoscopy (Assessed Centrally) — -0.23; -0.99 score on a scale — p== 0.062
Adherence
Primary: Medication Adherence - Pill Count — 0.46; 0.53 Probability of adherence (PT/PP => 0.8) — p=0.04
Brain Metastases · Breast Cancer · Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 53; 14; 35 Participants
Brain Tumor · Glioblastoma · Anaplastic Glioma
Primary: Maximum Tolerated Dose of Everolimus for Participants With Recurrent Malignant Gliomas — 5 mg
Recruitment
Primary: ACTNOW! Clinical Trial Knowledge Assessment Score — 93.89; 93.58; 94.88; 97.88 score
Parkinson's Disease
Primary: Normalized Beta Band Power (13-30 Hz) During aDBS — 0.26 Normalized median beta power — p=<0.001
Obesity, Childhood
Primary: Obesity of the Child (in the Mother-child Pair) During the First 5 Years of the Child's Life — 1845 Participants
Acute Repetitive Seizures · Breakthrough Seizures
Primary: Number of Participants Who Received NRL-1 (Valtoco) — 9; 54; 46; 54 Participants
Real World Data in China
Primary: the Modified TICI(Thrombolysis in Cerebral Infarction) Scale at the End of Procedure — 187 Participants